Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aficamten versus metoprolol in symptomatic obstructive hypertrophic cardiomyopathy
NL-OMON60657Phase 3Completed
- Sponsor
- Cytokinetics
- Start
- Feb 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of aficamten in hypertrophic cardiomyopathy (HCM) (2 arms), sponsored by Cytokinetics. Primary endpoint: Change in peak oxygen uptake. Started Feb 2024; status: completed.
02
Drugs
aficamten
03
Conditions
hypertrophic cardiomyopathy (HCM)
Beyond the preview
Go deeper on NL-OMON60657.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60657.